DRKS00015138招募中不适用
Toxicity and efficacy of combined stereotactic radiotherapy (SRT) and systemic targeted or immunotherapy - TOaSTT
niversitätsklinikum Freiburg, Klinik für Strahlenheilkunde0 个研究点目标入组 500 人开始时间: 2019年6月6日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Treatment of cerebral or extracerebral recurrence or metastatic tumor using stereotactic radiotherapy AND parallel treatment with targeted therapy (antibodies, small molecule drugs, immunotherapy).
- •Female and male subjects older than 18 years old
排除标准
- •Written or oral revocation of the informed consent for the storage and processing of patient data
研究者
相似试验
招募中
3 期
Efficacy and Safety of Fractionated Stereotactic Radiation Therapy (FSRT) versus Single Fraction Stereotactic Radiosurgery (SRS) for Large Brain Metastases (2 - 4 cm)C79.3Secondary malignant neoplasm of brain and cerebral meningesDRKS00015647niversitätsklinikum Erlangen382
终止
1 期
Stereotactic Body Radiotherapy (SBRT) and Sorafenib in Patients With Metastatic, Recurrent, or Unresectable Renal Cell Cancer (RCC)Renal Cell CarcinomaNCT00672178Duke University1
尚未招募
不适用
Effectiveness of radical stereotactic body radiotherapy for vertebral bone metastasisThe patients with vertebral bone metastasisJPRN-UMIN000045898Asahi University20
尚未招募
4 期
Efficacy of stereotactic radiosurgery based on three-dimensional rotational angiography for cerebrovascular malformatioBrain arteriovenous malformationcerebrovascular disease, cerebrovascular malformationD002538JPRN-jRCT1032230589mekawa Motoyuki60
进行中（未招募）
2 期
Stereotactic Radiotherapy for Oligoprogressive ER-positive Breast Cancer. AVATAR.ER-positive, HER2-negative advanced breast cancerCancer - BreastBreast CancerAdvanced breast cancerACTRN12620001212943Peter Mac Callum Cancer Centre32